Tumor-intrinsic and -extrinsic roles of c-Kit: Mast cells as the primary off-target of tyrosine kinase inhibitors

Oncogene

Volumn 30, Issue 7, 2011, Pages 757-769

  Pittoni, P ^a   Piconese, S ^a   Tripodo, C ^b   Colombo, M P ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

c Kit; mast cells; mouse mutants; off target; tyrosine kinase inhibitors

Indexed keywords

IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB;

ANGIOGENESIS; GENE FUNCTION; LOSS OF FUNCTION MUTATION; MAST CELL; NEOPLASM; ONCOGENE C KIT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR CELL; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MAST CELLS; MASTOCYTOSIS; MICE; NEOPLASM INVASIVENESS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; RATS; STEM CELL FACTOR;

EID: 79951811209     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.494     Document Type: Review

References (141)

1. Anderson DM, Williams DE, Tushinski R, Gimpel S, Eisenman J, Cannizzaro LA et al. (1991). Alternate splicing of mRNAs encoding human mast cell growth factor and localization of the gene to chromosome 12q22-q24. Cell Growth Differ 2: 373-378.
2. Andreu P, Johansson M, Affara NI, Pucci F, Tan T, Junankar S et al. (2010). FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell 17: 121-134.
3. Beaven MA. (2009). Our perception of the mast cell from Paul Ehrlich to now. Eur J Immunol 39: 11-25.
4. Bellone G, Smirne C, Carbone A, Buffolino A, Scirelli T, Prati A et al. (2006). KIT/stem cell factor expression in premalignant and malignant lesions of the colon mucosa in relationship to disease progression and outcomes. Int J Oncol 29: 851-859.
5. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K et al. (2000). Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2: 737-744.
6. Berrozpe G, Timokhina I, Yukl S, Tajima Y, Ono M, Zelenetz AD et al. (1999). The W(sh), W(57), and Ph Kit expression mutations define tissue-specific control elements located between -23 and -154 kb upstream of Kit. Blood 94: 2658-2666. (Pubitemid 29477294)
7. Besmer P, Murphy JE, George PC, Qiu FH, Bergold PJ, Lederman L et al. (1986). A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family. Nature 320: 415-421. (Pubitemid 16097805)
8. Blatner NR, Bonertz A, Beckhove P, Cheon EC, Krantz SB, Strouch M et al. (2010). In colorectal cancer mast cells contribute to systemic regulatory T-cell dysfunction. Proc Natl Acad Sci USA 107: 6430-6435.
9. Bodemer C, Hermine O, Palmerini F, Yang Y, Grandpeix-Guyodo C, Leventhal PS et al. (2010). Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol 130: 804-815.
10. Borg C, Terme M, Taieb J, Menard C, Flament C, Robert C et al. (2004). Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest 114: 379-388. (Pubitemid 39071610)
11. Broudy VC. (1997). Stem cell factor and hematopoiesis. Blood 90: 1345-1364.
12. Chabot B, Stephenson DA, Chapman VM, Besmer P, Bernstein A. (1988). The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature 335: 88-89.
13. Chen J, Schmitt A, Giannopoulos K, Chen B, Rojewski M, Dohner H et al. (2007). Imatinib impairs the proliferation and function of CD4+CD25+ regulatory T cells in a dose-dependent manner. Int J Oncol 31: 1133-1139.
14. Colombo MP, Piconese S. (2009). Polyps wrap mast cells and Treg within tumorigenic tentacles. Cancer Res 69: 5619-5622.
15. Corless CL, Heinrich MC. (2008). Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol 3: 557-586. (Pubitemid 351488293)
16. Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, Werb Z et al. (1999). Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 13: 1382-1397. (Pubitemid 29270244)
17. Coussens LM, Tinkle CL, Hanahan D, Werb Z. (2000). MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103: 481-490.
18. Crivellato E, Nico B, Ribatti D. (2008). Mast cells and tumour angiogenesis: new insight from experimental carcinogenesis. Cancer Lett 269: 1-6.
19. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H et al. (2005). Distinct sets of genetic alterations in melanoma. N Engl J Med 353: 2135-2147. (Pubitemid 41653105)
20. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J et al. (2006). Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368: 1329-1338. (Pubitemid 44528723)
21. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ et al. (2002). Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347: 472-480. (Pubitemid 34879334)
22. Dietz AB, Souan L, Knutson GJ, Bulur PA, Litzow MR, Vuk- Pavlovic S. (2004). Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 104: 1094-1099. (Pubitemid 39038030)
23. Dubreuil P, Letard S, Ciufolini M, Gros L, Humbert M, Casteran N et al. (2009). Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS One 4: e7258.
24. Freier K, Flechtenmacher C, Walch A, Devens F, Muhling J, Lichter P et al. (2005). Differential KIT expression in histological subtypes of adenoid cystic carcinoma (ACC) of the salivary gland. Oral Oncol 41: 934-939. (Pubitemid 41265953)
25. Fritsche-Polanz R, Fritz M, Huber A, Sotlar K, Sperr WR, Mannhalter C et al. (2010). High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V. Mol Oncol 4: 335-346.
26. Frossi B, Gri G, Tripodo C, Pucillo C. (2010). Exploring a regulatory role for mast cells: 'MCregs'? Trends Immunol 31: 97-102.
27. Gabrilovich DI, Nagaraj S. (2009). Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9: 162-174.
28. Gadd SJ, Ashman LK. (1985). A murine monoclonal antibody specific for a cell-surface antigen expressed by a subgroup of human myeloid leukaemias. Leuk Res 9: 1329-1336. (Pubitemid 16199173)
29. Galinsky DS, Nechushtan H. (2008). Mast cells and cancer-no longer just basic science. Crit Rev Oncol Hematol 68: 115-130.
30. Galli SJ, Grimbaldeston M, Tsai M. (2008). Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nat Rev Immunol 8: 478-486. (Pubitemid 351733419)
31. Galli SJ, Tsai M, Wershil BK. (1993). The c-kit receptor, stem cell factor, and mast cells. What each is teaching us about the others. Am J Pathol 142: 965-974. (Pubitemid 24060571)
32. Geissler EN, Ryan MA, Housman DE. (1988). The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene. Cell 55: 185-192.
33. Gilfillan AM, Rivera J. (2009). The tyrosine kinase network regulating mast cell activation. Immunol Rev 228: 149-169.
34. Gleixner KV, Mayerhofer M, Aichberger KJ, Derdak S, Sonneck K, Bohm A et al. (2006). PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood 107: 752-759. (Pubitemid 43076402)
35. Gomes AL, Reis-Filho JS, Lopes JM, Martinho O, Lambros MB, Martins A et al. (2007). Molecular alterations of KIT oncogene in gliomas. Cell Oncol 29: 399-408. (Pubitemid 47255978)
36. Gounaris E, Blatner NR, Dennis K, Magnusson F, Gurish MF, Strom TB et al. (2009). T-regulatory cells shift from a protective antiinflammatory to a cancer-promoting proinflammatory phenotype in polyposis. Cancer Res 69: 5490-5497.
37. Gounaris E, Erdman SE, Restaino C, Gurish MF, Friend DS, Gounari F et al. (2007). Mast cells are an essential hematopoietic component for polyp development. Proc Natl Acad Sci USA 104: 19977-19982.
38. Gri G, Piconese S, Frossi B, Manfroi V, Merluzzi S, Tripodo C et al. (2008). CD4+CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. Immunity 29: 771-781.
39. Grimbaldeston MA, Chen CC, Piliponsky AM, Tsai M, Tam SY, Galli SJ. (2005). Mast cell-deficient W-sash c-kit mutant Kit W-sh/W-sh mice as a model for investigating mast cell biology in vivo. Am J Pathol 167: 835-848. (Pubitemid 41216366)
40. Grimbaldeston MA, Nakae S, Kalesnikoff J, Tsai M, Galli SJ. (2007). Mast cell-derived interleukin 10 limits skin pathology in contact dermatitis and chronic irradiation with ultraviolet B. Nat Immunol 8: 1095-1104. (Pubitemid 47423757)
41. Gunawan B. (2008). Knock-in murine models of familial gastrointestinal stromal tumours. J Pathol 214: 407-409.
42. Heissig B, Hattori K, Dias S, Friedrich M, Ferris B, Hackett NR et al. (2002). Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 109: 625-637. (Pubitemid 34628725)
43. Hirashima K, Takamori H, Hirota M, Tanaka H, Ichihara A, Sakamoto Y et al. (2009). Multiple gastrointestinal stromal tumors in neurofibromatosis type 1: report of a case. Surg Today 39: 979-983.
44. Huang B, Lei Z, Zhang GM, Li D, Song C, Li B et al. (2008). SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. Blood 112: 1269-1279.
45. Huang S, Luca M, Gutman M, McConkey DJ, Langley KE, Lyman SD et al. (1996). Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential. Oncogene 13: 2339-2347. (Pubitemid 27026017)
46. Hutt KJ, McLaughlin EA, Holland MK. (2006). Kit ligand and c-Kit have diverse roles during mammalian oogenesis and folliculogenesis. Mol Hum Reprod 12: 61-69.
47. Ikeda H, Kanakura Y, Tamaki T, Kuriu A, Kitayama H, Ishikawa J et al. (1991). Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. Blood 78: 2962-2968.
48. Ingram DA, Yang FC, Travers JB, Wenning MJ, Hiatt K, New S et al. (2000). Genetic and biochemical evidence that haploinsufficiency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates in vivo. J Exp Med 191: 181-188.
49. Ishikawa T, Nakai N, Liu NN, Shiba K, Isozaki K, Matsuda I et al. (2009). in vivo effect of imatinib on progression of cecal GIST-like tumors in exon 17-type c-kit knock-in mice. Lab Invest 89: 1161-1168.
50. Izquierdo MA, Van der Valk P, Van Ark-Otte J, Rubio G, Germa-Lluch JR, Ueda R et al. (1995). Differential expression of the c-kit proto-oncogene in germ cell tumours. J Pathol 177: 253-258.
51. Johansson A, Rudolfsson S, Hammarsten P, Halin S, Pietras K, Jones J et al. (2010). Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy. Am J Pathol 177: 1031-1041.
52. Kemmer K, Corless CL, Fletcher JA, McGreevey L, Haley A, Griffith D et al. (2004). KIT mutations are common in testicular seminomas. Am J Pathol 164: 305-313. (Pubitemid 38364614)
53. Khalaf WF, Yang FC, Chen S, White H, Bessler W, Ingram DA et al. (2007). K-ras is critical for modulating multiple c-kit-mediated cellular functions in wild-type and Nf1+/- mast cells. J Immunol 178: 2527-2534. (Pubitemid 46233454)
54. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. (1998). Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 152: 1259-1269. (Pubitemid 28221878)
55. Kinet JP. (2007). The essential role of mast cells in orchestrating inflammation. Immunol Rev 217: 5-7.
56. Kitamura Y, Go S, Hatanaka K. (1978). Decrease of mast cells in W/Wv mice and their increase by bone marrow transplantation. Blood 52: 447-452. (Pubitemid 8395558)
57. Ko CD, Kim JS, Ko BG, Son BH, Kang HJ, Yoon HS et al. (2003). The meaning of the c-kit proto-oncogene product in malignant transformation in human mammary epithelium. Clin Exp Metastasis 20: 593-597. (Pubitemid 37463896)
58. Ko JS, Rayman P, Ireland J, Swaidani S, Li G, Bunting KD et al. (2010). Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res 70: 3526-3536.
59. Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P et al. (2009). Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 15: 2148-2157.
60. Krishnamoorthy N, Oriss TB, Paglia M, Fei M, Yarlagadda M, Vanhaesebroeck B et al. (2008). Activation of c-Kit in dendritic cells regulates T helper cell differentiation and allergic asthma. Nat Med 14: 565-573. (Pubitemid 351655220)
61. Krystal GW, Hines SJ, Organ CP. (1996). Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res 56: 370-376.
62. Larmonier N, Janikashvili N, LaCasse CJ, Larmonier CB, Cantrell J, Situ E et al. (2008). Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors. J Immunol 181: 6955-6963.
63. Lassam N, Bickford S. (1992). Loss of c-kit expression in cultured melanoma cells. Oncogene 7: 51-56.
64. Laurson J, Selden C, Clements M, Mavri-Damelin D, Coward S, Lowdell M et al. (2007). Putative human liver progenitor cells in explanted liver. Cells Tissues Organs 186: 180-191. (Pubitemid 47360941)
65. Leong KG, Wang BE, Johnson L, Gao WQ. (2008). Generation of a prostate from a single adult stem cell. Nature 456: 804-808.
66. Liegl B, Kepten I, Le C, Zhu M, Demetri GD, Heinrich MC et al. (2008). Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol 216: 64-74.
67. Liegl-Atzwanger B, Fletcher JA, Fletcher CD. (2010). Gastrointestinal stromal tumors. Virchows Arch 456: 111-127.
68. Liu H, Chen X, Focia PJ, He X. (2007). Structural basis for stem cell factor-KIT signaling and activation of class III receptor tyrosine kinases. Embo J 26: 891-901.
69. Lu LF, Lind EF, Gondek DC, Bennett KA, Gleeson MW, Pino-Lagos K et al. (2006). Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 442: 997-1002. (Pubitemid 44330250)
70. Lyon MF, Glenister PH. (1982). A new allele sash (Wsh) at the W-locus and a spontaneous recessive lethal in mice. Genet Res 39: 315-322. (Pubitemid 12024889)
71. Maeda H, Yamagata A, Nishikawa S, Yoshinaga K, Kobayashi S, Nishi K et al. (1992). Requirement of c-kit for development of intestinal pacemaker system. Development 116: 369-375.
72. Maeyama H, Hidaka E, Ota H, Minami S, Kajiyama M, Kuraishi A et al. (2001). Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene. Gastroenterology 120: 210-215. (Pubitemid 32061885)
73. Majumdar MK, Thiede MA, Haynesworth SE, Bruder SP, Gerson SL. (2000). Human marrow-derived mesenchymal stem cells (MSCs) express hematopoietic cytokines and support long-term hematopoiesis when differentiated toward stromal and osteogenic lineages. J Hematother Stem Cell Res 9: 841-848. (Pubitemid 32110282)
74. Maltby S, Khazaie K, McNagny KM. (2009). Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation. Biochim Biophys Acta 1796: 19-26.
75. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY et al. (2008). The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715. (Pubitemid 351636299)
76. Mantovani A, Allavena P, Sica A, Balkwill F. (2008). Cancer-related inflammation. Nature 454: 436-444.
77. Martin-Orozco N, Dong C. (2009). The IL-17/IL-23 axis of inflammation in cancer: friend or foe? Curr Opin Investig Drugs 10: 543-549.
78. Matsui Y, Zsebo KM, Hogan BL. (1990). Embryonic expression of a haematopoietic growth factor encoded by the Sl locus and the ligand for c-kit. Nature 347: 667-669. (Pubitemid 20356242)
79. Meininger CJ, Yano H, Rottapel R, Bernstein A, Zsebo KM, Zetter BR. (1992). The c-kit receptor ligand functions as a mast cell chemoattractant. Blood 79: 958-963.
80. Melani C, Sangaletti S, Barazzetta FM, Werb Z, Colombo MP. (2007). Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res 67: 11438-11446. (Pubitemid 350248572)
81. Menard C, Blay JY, Borg C, Michiels S, Ghiringhelli F, Robert C et al. (2009). Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Cancer Res 69: 3563-3569.
82. Molin D, Edstrom A, Glimelius I, Glimelius B, Nilsson G, Sundstrom C et al. (2002). Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma. Br J Haematol 119: 122-124. (Pubitemid 35176509)
83. Moller C, Alfredsson J, Engstrom M, Wootz H, Xiang Z, Lennartsson J et al. (2005). Stem cell factor promotes mast cell survival via inactivation of FOXO3a-mediated transcriptional induction and MEK-regulated phosphorylation of the proapoptotic protein Bim. Blood 106: 1330-1336. (Pubitemid 41129597)
84. Morales JK, Falanga YT, Depcrynski A, Fernando J, Ryan JJ. (2010). Mast cell homeostasis and the JAK-STAT pathway. Genes Immun 11: 599-608.
85. Musch W, Wege AK, Mannel DN, Hehlgans T. (2008). Generation and characterization of alpha-chymase-Cre transgenic mice. Genesis 46: 163-166. (Pubitemid 351554745)
86. Nakai N, Ishikawa T, Nishitani A, Liu NN, Shincho M, Hao H et al. (2008). A mouse model of a human multiple GIST family with KITA-sp820Tyr mutation generated by a knock-in strategy. J Pathol 214: 302-311. (Pubitemid 351212385)
87. Nakayama T, Yao L, Tosato G. (2004). Mast cell-derived angiopoietin-1 plays a critical role in the growth of plasma cell tumors. J Clin Invest 114: 1317-1325. (Pubitemid 40385303)
88. Natali PG, Nicotra MR, Sures I, Mottolese M, Botti C, Ullrich A. (1992). Breast cancer is associated with loss of the c-kit oncogene product. Int J Cancer 52: 713-717.
89. Nigrovic PA, Gray DH, Jones T, Hallgren J, Kuo FC, Chaletzky B et al. (2008). Genetic inversion in mast cell-deficient (W(sh)) mice interrupts corin and manifests as hematopoietic and cardiac aberrancy. Am J Pathol 173: 1693-1701.
90. Nocka K, Majumder S, Chabot B, Ray P, Cervone M, Bernstein A et al. (1989). Expression of c-kit gene products in known cellular targets of W mutations in normal and W mutant mice - evidence for an impaired c-kit kinase in mutant mice. Genes Dev 3: 816-826.
91. Nocka K, Tan JC, Chiu E, Chu TY, Ray P, Traktman P et al. (1990). Molecular bases of dominant negative and loss of function mutations at the murine c-kit/white spotting locus: W37, Wv, W41 and W. Embo J 9: 1805-1813.
92. Okayama Y, Kawakami T. (2006). Development, migration, and survival of mast cells. Immunol Res 34: 97-115. (Pubitemid 43997964)
93. Orr-Urtreger A, Avivi A, Zimmer Y, Givol D, Yarden Y, Lonai P. (1990). Developmental expression of c-kit, a proto-oncogene encoded by the W locus. Development 109: 911-923.
94. Ozao-Choy J, Ma G, Kao J, Wang GX, Meseck M, Sung M et al. (2009). The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 69: 2514-2522.
95. Palmu S, Soderstrom KO, Quazi K, Isola J, Salminen E. (2002). Expression of C-KIT and HER-2 tyrosine kinase receptors in poorprognosis breast cancer. Anticancer Res 22: 411-414. (Pubitemid 34475331)
96. Pan J, Quintas-Cardama A, Kantarjian HM, Akin C, Manshouri T, Lamb P et al. (2007). EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation. Blood 109: 315-322. (Pubitemid 46053072)
97. Paschka P, Marcucci G, Ruppert AS, Mrozek K, Chen H, Kittles RA et al. (2006). Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 24: 3904-3911. (Pubitemid 46630738)
98. Perez-Losada J, Sanchez-Martin M, Rodriguez-Garcia A, Sanchez ML, Orfao A, Flores T et al. (2002). Zinc-finger transcription factor Slug contributes to the function of the stem cell factor c-kit signaling pathway. Blood 100: 1274-1286. (Pubitemid 34864282)
99. Piconese S, Gri G, Tripodo C, Musio S, Gorzanelli A, Frossi B et al. (2009). Mast cells counteract regulatory T-cell suppression through interleukin-6 and OX40/OX40L axis toward Th17-cell differentiation. Blood 114: 2639-2648.
100. Pierotti MA, Negri T, Tamborini E, Perrone F, Pricl S, Pilotti S. (2010). Targeted therapies: the rare cancer paradigm. Mol Oncol 4: 19-37.
101. Robson ME, Glogowski E, Sommer G, Antonescu CR, Nafa K, Maki RG et al. (2004). Pleomorphic characteristics of a germline KIT mutation in a large kindred with gastrointestinal stromal tumors, hyperpigmentation, and dysphagia. Clin Cancer Res 10: 1250-1254. (Pubitemid 38365214)
102. Ronnstrand L. (2004). Signal transduction via the stem cell factor receptor/c-Kit. Cell Mol Life Sci 61: 2535-2548.
103. Rossi F, Ehlers I, Agosti V, Socci ND, Viale A, Sommer G et al. (2006). Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor. Proc Natl Acad Sci USA 103: 12843-12848. (Pubitemid 44298649)
104. Rubin BP, Antonescu CR, Scott-Browne JP, Comstock ML, Gu Y, Tanas MR et al. (2005). A knock-in mouse model of gastrointestinal stromal tumor harboring kit K641E. Cancer Res 65: 6631-6639. (Pubitemid 41060699)
105. Sakurai S, Hasegawa T, Sakuma Y, Takazawa Y, Motegi A, Nakajima T et al. (2004). Myxoid epithelioid gastrointestinal stromal tumor (GIST) with mast cell infiltrations: a subtype of GIST with mutations of platelet-derived growth factor receptor alpha gene. Hum Pathol 35: 1223-1230. (Pubitemid 39361645)
106. Scholten J, Hartmann K, Gerbaulet A, Krieg T, Muller W, Testa G et al. (2008). Mast cell-specific Cre/loxP-mediated recombination in vivo. Transgenic Res 17: 307-315.
107. Seggewiss R, Lore K, Greiner E, Magnusson MK, Price DA, Douek DC et al. (2005). Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 105: 2473-2479. (Pubitemid 40387048)
108. Shah NP, Lee FY, Luo R, Jiang Y, Donker M, Akin C. (2006). Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 108: 286-291. (Pubitemid 43990640)
109. Silvers WK. (1979). The Coat Colors of Mice-A Model for Mammalian Gene Action and Interaction. Springer Verlag: Berlin, Germany.
110. Sommer G, Agosti V, Ehlers I, Rossi F, Corbacioglu S, Farkas J et al. (2003). Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase. Proc Natl Acad Sci USA 100: 6706-6711.
111. Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB, Evan GI. (2007). Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med 13: 1211-1218. (Pubitemid 47530639)
112. Stanulla M, Welte K, Hadam MR, Pietsch T. (1995). Coexpression of stem cell factor and its receptor c-Kit in human malignant glioma cell lines. Acta Neuropathol 89: 158-165.
113. Staser K, Yang FC, Clapp DW. (2010). Mast cells and the neurofibroma microenvironment. Blood 116: 157-164.
114. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. (2008). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Fourth Edition. WHO Press: Geneva, Switzerland.
115. Taieb J, Chaput N, Menard C, Apetoh L, Ullrich E, Bonmort M et al. (2006). A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med 12: 214-219.
116. Tang Y, Liang X, Zheng M, Zhu Z, Zhu G, Yang J et al. (2010). Expression of c-kit and Slug correlates with invasion and metastasis of salivary adenoid cystic carcinoma. Oral Oncol 46: 311-316.
117. Taskinen M, Karjalainen-Lindsberg ML, Leppa S. (2008). Prognostic influence of tumor-infiltrating mast cells in patients with follicular lymphoma treated with rituximab and CHOP. Blood 111: 4664-4667.
118. Taylor AM, Galli SJ, Coleman JW. (1995). Stem-cell factor, the kit ligand, induces direct degranulation of rat peritoneal mast cells in vitro and in vivo: dependence of the in vitro effect on period of culture and comparisons of stem-cell factor with other mast cell-activating agents. Immunology 86: 427-433.
119. Teitell M, Rowland JM. (1998). Systemic mast cell disease associated with primary ovarian mixed malignant germ cell tumor. Hum Pathol 29: 1546-1547. (Pubitemid 28563993)
120. Theoharides TC. (2008). Mast cells and pancreatic cancer. N Engl J Med 358: 1860-1861.
121. Theoharides TC, Conti P. (2004). Mast cells: the Jekyll and Hyde of tumor growth. Trends Immunol 25: 235-241. (Pubitemid 38501669)
122. Tono T, Tsujimura T, Koshimizu U, Kasugai T, Adachi S, Isozaki K et al. (1992). c-kit Gene was not transcribed in cultured mast cells of mast cell-deficient Wsh/Wsh mice that have a normal number of erythrocytes and a normal c-kit coding region. Blood 80: 1448-1453.
123. Tournilhac O, Santos DD, Xu L, Kutok J, Tai YT, Le Gouill S et al. (2006). Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling. Ann Oncol 17: 1275-1282. (Pubitemid 44288218)
124. Tripodo C, Gri G, Piccaluga PP, Frossi B, Guarnotta C, Piconese S et al. (2010). Mast Cells and Th17 Cells Contribute to the Lymphoma-Associated Pro-Inflammatory Microenvironment of Angioimmunoblastic T-Cell Lymphoma. Am J Pathol 177: 792-802.
125. Tsuda H, Tani Y, Weisenberger J, Kitada S, Hasegawa T, Murata T et al. (2005). Frequent KIT and epidermal growth factor receptor overexpressions in undifferentiated-type breast carcinomas with 'stem-cell-like' features. Cancer Sci 96: 333-339.
126. Wasiuk A, de Vries VC, Hartmann K, Roers A, Noelle RJ. (2009). Mast cells as regulators of adaptive immunity to tumours. Clin Exp Immunol 155: 140-146.
127. Weinstein IB, Joe A. (2008). Oncogene addiction. Cancer Res 68: 3077-3080.
128. Westphal E. (1891). Uber mastzellen. In: Ehrlich P (ed). Ferbenanlytische Untersuchungen Zur Histologie Und Klinik Des Blutes. Hirschwald: Berlin, pp 17-41.
129. Winship I, Young K, Martell R, Ramesar R, Curtis D, Beighton P. (1991). Piebaldism: an autonomous autosomal dominant entity. Clin Genet 39: 330-337.
130. Woodman SE, Davies MA. (2010). Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. Biochem Pharmacol 80: 568-574.
131. Yang FC, Ingram DA, Chen S, Hingtgen CM, Ratner N, Monk KR et al. (2003). Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for Nf1+/- mast cells. J Clin Invest 112: 1851-1861. (Pubitemid 38063708)
132. Yang FC, Ingram DA, Chen S, Zhu Y, Yuan J, Li X et al. (2008). Nf1-dependent tumors require a microenvironment containing Nf1+/- and c-kit-dependent bone marrow. Cell 135: 437-448.
133. Yang FC, Kapur R, King AJ, Tao W, Kim C, Borneo J et al. (2000). Rac2 stimulates Akt activation affecting BAD/Bcl-XL expression while mediating survival and actin function in primary mast cells. Immunity 12: 557-568.
134. Yang Z, Zhang B, Li D, Lv M, Huang C, Shen GX et al. (2010). Mast cells mobilize myeloid-derived suppressor cells and Treg cells in tumor microenvironment via IL-17 pathway in murine hepatocarcinoma model. PLoS One 5: e8922.
135. Yared MA, Middleton LP, Meric F, Cristofanilli M, Sahin AA. (2004). Expression of c-kit proto-oncogene product in breast tissue. Breast J 10: 323-327. (Pubitemid 38924469)
136. Young SM, Cambareri AC, Odell A, Geary SM, Ashman LK. (2007). Early myeloid cells expressing c-KIT isoforms differ in signal transduction, survival and chemotactic responses to Stem Cell Factor. Cell Signal 19: 2572-2581. (Pubitemid 47542299)
137. Zappulla JP, Dubreuil P, Desbois S, Letard S, Hamouda NB, Daeron M et al. (2005). Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation. J Exp Med 202: 1635-1641. (Pubitemid 41815869)
138. Zaruba MM, Soonpaa M, Reuter S, Field LJ. (2010). Cardiomyogenic potential of C-kit(+)-expressing cells derived from neonatal and adult mouse hearts. Circulation 121: 1992-2000.
139. Zhu Y, Ghosh P, Charnay P, Burns DK, Parada LF. (2002). Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science 296: 920-922. (Pubitemid 34464899)
140. Zsebo KM, Williams DA, Geissler EN, Broudy VC, Martin FH, Atkins HL et al. (1990). Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell 63: 213-224.
141. Zudaire E, Martinez A, Garayoa M, Pio R, Kaur G, Woolhiser MR et al. (2006). Adrenomedullin is a cross-talk molecule that regulates tumor and mast cell function during human carcinogenesis. Am J Pathol 168: 280-291. (Pubitemid 43062580)